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Abstract 
Natural killer (NK) cells are effectors in innate immunity, but also participate in 
immunoregulation through the release of transforming growth factor (TGF)-β1 
and lysis of activated/autoreactive T cells. Apoptotic cells (ACs) have been shown 
to induce tolerogenic properties of innate immune cells, including macrophages 
and dendritic cells, but not NK cells. In this study, we demonstrated that after 
interaction with ACs, NK cells released TGF-β1, which in turn suppressed the 
production of interferon (IFN)-γ by NK cells upon IL-12 and IgG activation. We 
further identified phosphatidylserine (PS) as a potential targets on ACs for the NK 
cells, since PS could stimulate NK cells to release TGF-β1, which in turn 
suppressed CD4+ T cell proliferation and activation. Moreover, AC-treated NK 
cells displayed cytotoxicity against autologous activated CD4+ T cells by 
upregulating NKp46. We then identified that this lysis occurs in part through 
NKp46-Vimentin pathway, since activated CD4+ T cells expressed vimentin on 
cell surface and blocking of vimentin or NKp46, but not other NK cell receptors, 
significantly suppressed the NK cell cytotoxicity. We report here a novel 
interaction between NK cells and ACs resulting in the tolerogenic properties of 
NK cells required for immune contraction.
 4 
Introduction 
Natural killer (NK) cells are the front line players of innate immunity, involved in 
eliminating virus infected cells and transformed cells [1]. NK cells also promote 
inflammation, with release of high levels of pro-inflammatory cytokines and 
chemokines. However, recent observations revealed that they are important in 
immune regulation and linking the innate and adaptive immunity [2]. NK cells 
could regulate immune responses by production of cytokines, including interferon 
(IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-10 [3]. 
Martin-Fontecha et al. further demonstrated that NK cells can release IFN-γ for 
Th1 polarization in vivo [4]. Moreover, activated NK cells could acquire antigen 
presentation cells phenotype with upregulation of CD86 and MHC class II 
molecules to enhance T cell proliferation and activation [5].  
 
Although NK cells participate in promoting inflammation and Th1 polarization, 
deficient NK cell functions and cytotoxicity are associated with autoimmune 
diseases, including systemic lupus erythematosus, rheumatoid arthritis and 
multiple sclerosis [6,7]. These observations suggest that NK cells help maintain 
homeostasis of the immune system. They may play a role in peripheral tolerance 
 5 
as they can produce transforming growth factor (TGF)-β1 [8], which is further 
enhanced by coculturing with anti-CD2 antibody [9] and soluble HLA-I [10]. In 
vivo mouse model confirmed that TGF-β1 producing NK cells can inhibit Th1 
response by suppressing self production of IFN-γ [11]. Furthermore, NK cells 
display cytolytic activity against autologous immune cells such as DCs and T 
cells. Lysis of immature DCs by NK cells through NKp30 can limit the number of 
mature DCs and prevent over presentation of antigens to T cells [12]. NK cells 
also eliminate autoreactive T cells in experimental autoimmune encephalomyelitis 
(EAE) mouse model resulting in less disease severity [13,14]. Cerboni et al. 
demonstrated that IL-2 activated NK cells lyse autologous activated CD4+ T cells 
through NKG2D/NKG2DLs interaction in vitro [15].  
 
Apoptotic cells (ACs) are self antigens that induce tolerogenic properties of innate 
immune cells such as macrophages and DCs which can recognize and 
phagocytose ACs [16-18]. After ingestion of ACs, macrophages can release 
TGF-β1 to resolve inflammation in vivo of the LPS-stimulated lungs [19]. DCs 
similarly produce TGF-β1 and IL-10 after ingestion of ACs and acquire the 
antigen presenting cells (APCs) phenotype with homing capability to lymph 
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nodes [17,18], inducing T cell tolerance by immunosuppressive cytokine 
production and/or self antigen presentation [20]. Therefore, ACs can induce 
immune tolerance when they are recognized by macrophages and DCs under 
physiologic status. However, the interaction between ACs and NK cells has not 
been studied. 
 
During inflammation, NK cells are recruited to induce apoptosis of virus infected 
cells or transformed cells. Previous studies demonstrated that NK cells are 
inactivated after killing of sensitive target cells [21,22]. We hypothesize these 
resulting ACs can negatively feedback on NK cells for immune contraction. In 
this study, we designed our in vitro model to reprise the interaction between NK 
cells and ACs, investigating whether NK cells become tolerogenic. 
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Results 
AC-treated NK cells released TGF-β1 to suppress self production of IFN-γ 
More than 95% of Jurkat T cells and autologous CD4+ T cells became Annexin 
V+ and propidium iodide+ after 50 hr of UV irradiation (Fig. S1). We first 
investigated the production of TGF-β1 by NK cells after cocultured with apoptotic 
Jurkat T cells (ACJur) (Fig. 1A) or apoptotic autologous CD4+ T cells (ACCD4) 
(Fig. 1B) for 36 hr. Untreated NK cells and ACs alone were used as negative 
controls and only minimal levels of TGF-β1 were detected (Fig. 1A and B). We 
observed that both ACJur- and ACCD4-treated NK cells released significantly 
higher level of TGF-β1 when compared with untreated NK cells (P< 0.05, n= 5) 
(Fig. 1A and B). Other cytokines, including IFN-γ and TNF-α, were not detected 
in any conditions (data not shown). 
 
Since TGF-β1 could down-regulate NK cell function in terms of IFN-γ production 
[11, 23], we hypothesized that ACs may inhibit IFN-γ production from NK cells 
by promoting NK cells to release TGF-β1. We first demonstrated that 
ACJur-treated NK cells were less responsive to IL-12 in producing IFN-γ (Fig. 
1C). To further delineate the mechanism of this phenomenon, we blocked the 
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function of TGF-β1 by adding TGF-β1 neutralization antibody to the culture. We 
observed the inhibition of IFN-γ on IL-12 response was partially reversed (Fig. 
1C). We also prepared IgG-opsonized ACJUR (Fig S2) to activate NK cells 
through Fcγ receptors to release IFN-γ (Fig.1D). Similar to IL-12 activation, the 
addition of TGF-β1 neutralization antibody significantly enhanced the IFN-γ 
production by NK cells. Thus, TGF-β1 was partially responsible for the 
suppression of IFN-γ production from NK cells observed in our experiments. 
ACJUR alone did not have IFN-γ production (data not shown). 
 
NK cells released TGF-β1 after interaction with Phosphatidylserine (PS) 
PS is exposed on cell surface during apoptosis [24] and the interaction of ACs 
with phagocytes through PS resulted in the production of TGF-β1 [19]. Therefore, 
we have used apoptotic PLB-985 cells (ACPLB), which do not expose PS on the 
cell surface during apoptosis [19], to investigate the role of PS on ACs to induce 
TGF-β1 production from NK cells. We observed that ACPLB was not able to 
induce TGF-β1 production from NK cells (Fig 2A). Then, we investigated 
whether PS alone could stimulate NK cells to release TGF-β1. After cocultured 
with PS, NK cells released TGF-β1 in a PS dose-dependent manner (Fig. 2B) and 
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the percentage of TGF-β1+ NK cells was also increased (Fig. 2C). We have also 
screened for the expression of several PS receptors, i.e. CD36, Tim-1 and Tim-4, 
in resting, IL-2 activated, ACJUR- and PS-treated NK cells by flow cytometry, but 
none of them were detected (data not shown).  
 
PS-treated NK cells inhibited the proliferation and activation of autologous 
CD4+ T cells 
We next investigated the regulatory role of these PS-treated NK cells on the 
proliferation and activation of autologous CD4+ T cells. CD4+ T cells were 
activated with immobilized anti-CD3 antibody. After adding of NK cells that were 
pre-treated with 50µg of PS, the percentage of dividing activated CD4+ T cells 
was decreased from ~80% to ~40% as determined by flow cytometric CFSE 
assays (Fig. 3A). Also, 50µg PS-treated NK cells suppressed the expression of 
CD25, a T cell activation marker, of activated CD4+ T cells from ~85% to ~30% 
(Fig. 3B). 
 
Since PS-treated NK cells released TGF-β1, which could inhibit T cell 
proliferation and activation [25], we added TGF-β1 neutralization antibody to 
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investigate whether TGF-β1 was involved in the suppression of the CD4+ T cells 
observed in our system. The addition of the antibody partially restored the 
proliferation (Fig. 4A) and CD25 expression (Fig. 4B) of CD4+ T cells. Therefore, 
TGF-β1 was involved in the inhibitory effect of PS-treated NK cells on CD4+ T 
cells. 
 
To further investigate the mechanism of T cells suppression by PS-treated NK 
cells, we have investigated the cytotoxicity of PS-treated NK cells against 
anti-CD3-activated autologous CD4+ T cells. However, the cytotoxicity was not 
increased (data not shown). Thus, the suppression of activated T cells by 
PS-treated NK cells is independent of direct cell lysis. 
 
ACJUR-treated NK cells displayed higher cytotoxicity against autologous 
activated CD4+ T cell 
Previous studies have highlighted the potential role of NK cells in T cell 
surveillance by cytotoxicity [26]. We hypothesized that NK cells may suppress 
CD4+ T cells through their cytolytic activities after cocultured with ACs. 
Therefore, we cocultured ACJUR-treated NK cells with autologous PHA activated 
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CD4+ T cells and the cytotoxicity was determined by both cytoloytic and CD107a 
assays. As shown in Fig. 5A, ACJUR-treated NK cells displayed higher 
cytotoxicity against autologous PHA activated CD4+ T cells at NK cells to T cells 
ratio of 50:1 when compared with untreated NK cells (P< 0.05, n= 6, Fig. 5A). 
Similar phenomenon was observed when using autologous PMA/Ionomycin 
activated CD4+ T cells (data not shown). For autologous resting CD4+ T cells, 
both ACJUR-treated and untreated NK cells displayed minimal cytotoxicity (Fig. 
5A). Consistent with the cytolytic assay, ACJUR-treated NK cells expressed higher 
CD107a, a marker of degranulation in NK cells, when they were cocultured with 
activated autologous CD4+ T cells (Fig. 5B). We have performed the control 
experiments to coculture activated CD4+ T cells with ACs alone and there was no 
significant increase of T cell death when compared with activated CD4+ T cells 
alone. 
 
ACJUR-treated NK cells mediated lysis of autologous activated CD4+ T cell 
through NKp46 pathway 
To determine the NK cell receptor(s) responsible for direct killing of autologous 
activated CD4+ T cells, we determined the surface expressions of the three natural 
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cytotoxicity receptors (NCRs), i.e. NKp30, NKp44, NKp46, and also NKG2D on 
ACJUR-treated NK cells (Fig. 6A). We observed that NKp46 was significantly 
upregulated on ACJUR-treated NK cells (MFI: 18.76 ± 2.01), when compared with 
untreated NK cells (MFI: 13.07 ± 1.41) (P< 0.05; n= 6) (Fig. 6B).  
 
To confirm the role of NKp46 in autologous activated CD4+ T cell killing, we 
blocked NKp46 on AC-treated NK cells by using NKp46 blocking antibody. After 
blocking, the cytotoxicity of ACJUR-treated NK cells against autologous PHA 
activated CD4+ T cells was significantly reduced when compared with the isotype 
control (P< 0.05, n= 4) (Fig. 6C). Therefore NKp46 was involved in the killing of 
autologous activated CD4+ T cells by ACJUR-treated NK cells. We have also 
investigated the role of ICAM-1, 2B4 and TGF-β1 in this killing by using 
corresponding neutralization antibodies, however, no significant change was 
observed (data not shown). 
 
To investigate the role of PS in upregulating NKp46 expression and cytotoxicity 
of AC-treated NK cells, we incubated NK cells with ACJUR or ACPLB and 
observed that NKp46 levels were significantly upregulated in both treatments with 
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comparable levels (Fig S3A). Moreover, PS-treated NK cells did not show 
increase cytotoxicity against autologous PHA-activated CD4+ T cells (Fig S3B). 
Thus, the increased cytotoxicity of AC-treated NK cells was independent to PS on 
ACs. 
 
NK cells killed activated CD4+ T cells through NKp46-vimentin pathway 
Nolte-'t Hoen et al. reported that NK cells recognize and bind mitotic T cells 
through NKp46 [27], with our own observation, we hypothesized that activated T 
cells may express NKp46 ligand(s) through which NK cell cytotoxicity is 
mediated. Vimentin, an intermediate filament protein expressed on the surface of 
Sezary cells [28], TNF-α activated macrophages [29] and Mycobacterium 
tuberculosis-infected monocytes [30], has been reported as a NKp46 ligand that 
can induce the cytolytic activity of NK cells [30]. Therefore, we investigated the 
surface expression of vimentin on activated CD4+ T cells and its role in mediating 
NK cell cytotoxicity. 
 
We observed that the percentages of surface vimentin expressing cells in PHA 
(13.1 ± 2.2%) and PMA/Ionomycin (24.9 ± 1.9%) activated CD4+ T cells were 
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significantly higher than in resting CD4+ T cells (7.0 ± 2.9%) with P< 0.05 and 
0.005 respectively (n= 4) (Fig. 7A). In concordance with Garg et al.(29), we 
confirmed that vimentin is a NKp46 ligand as anti-vimentin antibody could block 
the binding of NKp46-Ig fusion protein on PHA activated CD4+ T cells (Fig. 7B). 
Then, we demonstrated that the cytotoxicity of ACJUR-treated NK cells against 
PHA-activated CD4+ T cells was significantly reduced after pre-incubation of 
these T cells with anti-vimentin antibody (P< 0.005, n= 4) (Fig. 7C). However, 
double blocking of NKp46 and vimentin by using neutralization antibodies did 
not further suppress the cytotoxicity (Fig. 7C). Therefore, we concluded that 
vimentin is one of the ligands that could be recognized by NKp46 and this 
recognition leads to killing of activated CD4+ T cell by NK cells. 
 
NK cells did not phagocytose ACs 
ACs are usually phagocytosed by macrophages and DCs through the recognition 
of PS [16-18]. It is possible that NK cells may also phagocytose ACs as we have 
demonstrated that NK cells could interact with both ACs and PS. However, 
confocal microscopy analysis showed that NK cells did not uptake ACJUR up to 
48hr (data not shown).
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Discussion 
In this study, we demonstrated a novel interaction between NK cells and ACs 
resulting in NK cells acquiring tolerogenic properties mediated by release of 
TGF-β1 in suppressing the production of IFN-γ by NK cells. This interaction 
involve recognition by NK cells of PS on the ACs, since PS-treated NK cells also 
released TGF-β1 resulting in inhibition of CD4+ T cell proliferation and activation. 
We further identified after interaction with ACs, these NK cells killed activated 
CD4+ T cells by recognizing T cell surface vimentin via its increased expression 
of NKp46. 
 
In vivo studies confirmed NK cells can trigger Th1 response as they are the initial 
source of IFN-γ (4), while TGF-β1 producing NK cells suppress Th1 response by 
inhibiting self production of IFN-γ [11]. In this study, we demonstrated that NK 
cells released TGF-β1 to suppress their own IFN-γ production after interaction 
with ACs (Fig. 1C and D). This is an important negative feedback mechanism 
initiated by NK cells for the normal termination of inflammation and Th1 immune 
responses. We also observed that TGF-β1 only partially responsible for the 
suppression of IFN-γ (Fig. 1C). Factors other than TGF-β1 are therefore involved 
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in this inhibition. As reported by Fadok et al., macrophages after having ingested 
ACs release platelet-activating factor (PAF) to inhibit the production of 
pro-inflammatory cytokines [16]. Since NK cells also produce PAF [31], future 
studies are required to identify other immunosuppressive factors including PAF 
that can be released by AC-treated NK cells to inhibit self production of IFN-γ. 
 
PS is exposed on the outer leaflet of plasma membrane during apoptosis and is the 
ligand recognized on ACs by phagocytes to produce TGF-β1 [19, 26, 32, 33]. NK 
cells express a wide range of receptors for pattern recognition, including toll like 
receptors, c-type lectins and scavenger receptors [34, 35], which can participate in 
recognition of ACs and PS. We demonstrated that PS is also the ligand with 
which NK cells interact to produce TGF-β1 and suppress the activation and 
proliferation of CD4+ T cells. We have therefore screened for the expression of 
several known PS receptors, i.e. CD36, Tim-1 and Tim-4, in resting, IL-2 
activated, AC- and PS-treated NK cells by flow cytometry. However, no known 
tested PS receptors were found (data not shown). Further studies are required to 
identify the possible PS receptor on NK cells. 
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Recognition of PS on ACs by phagocytes always leads to two events: (1) the 
engulfment of ACs by phagocytes, which is initiated by the “eat me” signal [32]; 
(2) production of immunosuppressive cytokines, including TGF-β1 and IL-10 
[16-19,33]. However, we only observed the production of TGF-β1 from AC- or 
PS-treated NK cells but not the uptake of ACs by NK cells. This indicated that 
these two events could occur independently and they are not necessarily 
associated. 
 
Surprisingly, AC-treated NK cells are more potent in killing autologous activated 
CD4+ T cells (Fig. 5) although they release TGF-β1 that is known to suppress NK 
cell cytotoxicity [20]. It becomes understandable when we observed that only 
NKp46 was upregulated in AC-treated NK cells (Fig 5A), as TGF-β1 can only 
suppress NK cell cytotoxicity through down-regulation of NKp30 and NKG2D 
but not NKp44 and NKp46 [36]. We further identified vimentin expressed on 
activated CD4+ T cell surface as a ligand for NKp46 to induce NK cell 
cytotoxicity (Fig. 6 and 7). Killing of activated T cells by NK cells is critical in 
terminating immune responses, as highlighted in familial hemophagocytic 
lymphohistiocytosis, a form of primary immunodeficiency associated with 
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defective NK cell cytotoxicity that leads to accumulation and infiltration of 
activated T cells and macrophages after infection [37]. We proposed that at the 
late phase of inflammation, NK cells encounter a lot of ACs, resulting in 
upregulation of NKp46, and lysis of activated T cell through the NKp46-vimentin 
pathway, and are the regulatory cells for immune contraction. 
 
Although NKG2D-NKG2DLs pathway has been shown to be responsible for IL-2 
activated NK cells regulation of the activatied CD4+ T cell survival [15], the 
expression levels of NKG2D of AC-treated NK cells in our study were similar to 
untreated NK cells; therefore, it is unlikely that NKG2D is responsible for the 
differential killing of autologous PHA activated CD4+ T cells. Therefore NK cells 
lyse activated or autoreactive T cells through different receptors, dependent on the 
initial stimulation. 
 
In conclusion, we identified a novel interaction that ACs can induce tolerogenic 
properties of NK cells, which are mediated through production of TGF-β1 and 
increase of cytotoxicity against activated CD4+ T cells. Defective NK cell 
functions in autoimmune diseases, such as systemic lupus erythematosus, 
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rheumatoid arthritis and multiple sclerosis; and primary immunodeficiences, such 
as familial hemophagocytic lymphohistiocytosis, have already highlighted the 
critical role of NK cells in the termination of immune responses. Future in-vivo 
studies that focus on NK cells in immune contraction should be performed. 
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Materials and Methods 
AC induction 
Jurkat T cells, PLB-985 cells and purified CD4+ cells were used as the source of 
ACs. As described in our previous studies [18], apoptosis was induced by UV 
irradiation (80 mJ/cm2) in a Spectrolinker UV Crosslinkers (Spectroline, NY, US). 
Irradiated cells were cultured in RPMI 1640 medium (Gibco, CA, US) with 0.4% 
BSA (Sigma-Aldrich, St. Louis, MO) at 37°C in 5% CO2 to undergo apoptosis for 
50 hours. Apoptosis was evaluated by apoptosis detection kit (Immunotech, 
Marseilles, France) by flow cytometry. Cells were stained by Annexin VFITC and 
propidium iodide according to the manufacturer’s protocol. ACs were incubated 
with purified human IgG (EMD BioSciences, Inc. La Jolla, CA) at 1 mg/ml for 1 
hr. After washed twice by PBS, the secondary antibody, FITC conjugated goat 
anti-human IgG antibody, was added for an additional 30 min for elevating the 
opsonization of human IgG by flow cytometry. 
 
Cell isolation 
Peripheral blood mononuclear cells (PBMCs) from peripheral blood of healthy 
blood donors were isolated by standard sedimentation over Ficoll-Hypaque 
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(Amersham Pharmacia Biotech, Piscataway, NJ). This study was conducted in 
accordance with the Declaration of Helsinki and was approved by the Institutional 
Review Board of the University of Hong Kong / Hospital Authority Hong Kong 
West Cluster. NK cells were negatively selected from PBMC by NK Isolation Kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The isolated population was 
>94% CD56+ CD3- as determined by flow cytometry. Contamination of CD3+, 
CD14+ and CD19+ was <2%. CD4+ cells were positively selected by anti-CD4 
immunomagnetic beads with purity consistently >97%. 
 
NK cell culture 
Isolated NK cells were cultured with RPMI 1640 medium containing 1% BSA at 
37°C in 5% CO2 at 24-well plates at a concentration of 5 x 105 cell/ml. ACs were 
added to the NK culture for 36 hr at NK cells to ACs ratio of 1:5. In some cases, 
NK cells were cocultured with ACs with reagents (2 ng/ml of IL-12, 10 µg/ml of 
anti-TGF-ß1 antibody or isotype control antibody). 
 
Cytokine detection 
The cytokines in the supernatant from the coculture of NK cells and ACs were 
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detected by DuoSet ELISA Development System (R&D Systems, Minneapolis, 
MN).  
 
PS treatment 
PS in chloroform (Avanti Polar Lipids, Alabaster, AL) was diluted by ethanol and 
dried in 96 well plate. 2 x 105 of NK cells were added to the well with 1% BSA 
and 30 IU/ml of IL-2 in RPMI 1640 medium for 24 hours. 
 
Intracellular cytokine staining 
PS-treated NK cells (2 x 105 per well) were incubated with 10 µg/ml Brefeldin A. 
After 5 hours, cells were stained with antibodies to surface CD56. Fixation and 
permeabilization were carried out by using intracellular staining kit (BD 
Bioscinences, San Diego, CA) and intracellular anti-TGF-β1 antibody (IQ 
products, Groningen, The Netherlands). 
 
T cell proliferation assays 
CD4+ T cells were labeled with carboxyfluorescein diacetate succinimidyl ester 
(CFSE) before activation. 5 x 104 of these labeled cells were cultured with 
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different numbers of the PS-treated NK cells at indicated ratios for 5 days with 
immobilized anti-CD3 antibody. Fcγ receptor blocking reagent (Miltenyi Biotec) 
was added to block the Fcγ receptor of NK cells. Cell division accompanied by 
CFSE dilution was analyzed by flow cytometry. CD4+ T cell proliferation was 
also analyzed by [3H] thymidine incorporation assay as described previously 
[38,39]. 
 
Cytolytic and CD107a assays 
The cytolytic activities of NK cells after cocultured with ACJUR were determined 
by Live/Dead cell-mediated cytotxicity kit (Molecular Probes, Eugene, Ore) and 
the expression of CD107a on NK cell surface. Autologous CD4+ T cells were 
activated by PHA (5µg/ml) for 2 days or PMA/Ionomycin (10ng/100ng 
respectively) for 1 day. After the activation, they were seeded in 96-well plates as 
target cells and NK cells were added as effector cells at the indicated 
effector/target cell ratio. 
 
Blocking experiment 
Blocking experiments were performed by pre-incubating ACJUR-treated NK cells 
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with saturating amounts of each of the 3 NCRs and NKG2D blocking antibodies 
(10-20 µg/ml) for 30 min. PHA activated CD4+ T cells were pre-incubated with 
anti-vimentin antibody (20 µg/ml) for 30 min. Corresponding isotype antibody 
was added as control. 5 x 105 ACJUR-treated NK cells were cocultured with 1 x 
104 PHA activated autologous CD4+ T cells for 2 hr for the cytolytic assay. 
 
Antibodies 
Mouse antibodies directly conjugated with FITC, PE or PE-Cy5.5 were used 
(clone): CD3 (UCHT1), CD4 (13B8.2), CD14 (RM052), CD19 (HIB19), CD56 
(NCAM16.2), CD107a (H4A3), NKG2D (1D11), NKp30 (30-15), NKp44 
(P44-8.1), NKp46 (9E2). They were purchased from BD and Beckman Coulter 
(Miami, FL). Purified mouse antibodies for blocking experiments were: TGF-β1 
(141322), NKp30 (P30-15), NKp44 (P44-8), NKp46 (9E2) and NKG2D (1D11) 
purchased from Biolegend (San Diego, CA), Beckman Coulter and R&D Systems. 
Goat anti-human IgG (H+L) and Rabbit anti-goat IgG (H+L) antibodies 
conjugated with FITC were purchased from Invitrogen (Carlsbad, CA). Goat 
anti-human vimentin polyclonal antibody was purchased from R&D Systems. 
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Statistical analysis 
Graphs and statistical analyses were performed with the use of Prism5.00 for 
Windows software (GraphPad Software, San Diego, CA). Pair t-test was used for 
two columns comparison and ANOVA was used when more than two columns are 
shown. P value of 0.05 or less was considered significant. 
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Figure 1. 
AC-treated NK cells released TGF-β1 to inhibit self production of IFN-γ. 
(A,B) NK cells were incubated with (A) ACJUR or (B) ACCD4 for 36 hr. 
Supernatants were collected for the detection of total TGF-β1 by ELISA. 
Untreated NK cells and ACs alone were used as negative controls *P < 0.05, 
paired t-test. (C) NK cells were incubated with IL-12 (2ng/ml) and/or ACJUR in 
the presence/absence of anti-TGF-β1 neutralizing antibody (10µg/ml) or an 
isotype control. Supernatants were collected for IFN-? detection by ELISA. *P< 
0.05, ANOVA. (D) NK cells were incubated with ACJUR or IgG-opsonized ACJUR 
for 36 hr in the presence/absence of TGF-β1 neutralizing antibody (10µg/ml) or 
an isotype control and IFN- γ production measured by ELISA. *P<0.05, ANOVA. 
Data are displayed as the mean cytokine production ± SEM for at least 4 
independent experiments. ND: Not detected. 
 
Figure 2. 
The interaction of NK cells with PS induces TGF-β1 production. (A) NK cells 
were cocultured with ACJUR or ACPLB or cultured alone for 36 hr and TGF-β1 
production measured by ELISA. (B,C) NK cells were cultured with 30 IU/ml of 
IL-2 in 96-well plates coated with PS at the indicated concentrations for 24 hr. (B) 
TGF-β1 production was determined by ELISA after 24hr. (C) Intracellular 
staining using PE conjugated anti-TGF-β1 antibody. Representative flow 
cytometry data are shown in the left and middle panels. Combined data (n=4) in 
the right panel. Data are mean ± SEM for 4 independent experiments. * P < 0.05, 
**P < 0.01, by (A, B) ANOVA and (C) paired t-test. 
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Figure 3. 
PS-treated NK cells inhibit proliferation and activation of CD4+ T cells. (A,B) 
5 x 104 CFSE-labeled autologous CD4+ T cells were left unstimulated or 
stimulated with plate-bound anti-CD3 and 2.5 x 104 NK cells (untreated or treated 
with 25 or 50µg PS) were added. (A) The intensities of CFSE were determined by 
flow cytometry at day 5 (B) APC-conjugated anti-CD25 antibody was used to 
determine surface expression of CD25 on the CD4+ cells. Grey histogram: isotype 
control; black line: CD25. The data are representative of 3 independent 
experiments. 
 
Figure 4. 
PS-treated NK cells inhibit proliferation and activation of CD4+ T cells 
through TGF-β1. (A,B) 5 x 104 CFSE-labeled autologous CD4+ T cells were 
stimulated with plate-bound anti-CD3 and PS-treated NK cells (50 µg PS) were 
added according to the indicated ratios. 10 µg/ml of TGF-β1 neutralizing antibody 
or an isotype control antibody were added to the culture. (A) [3H]-Thymidine 
incorporation was determined after 3 days. (B) Surface expression of CD25 was 
determined by flow cytometry at day 3. Data are displayed as the mean ± SEM for 
3 independent experiments. * P < 0.05, paired t-test. 
 
Figure 5. 
ACJUR-treated NK cells mediate lysis of autologous activated CD4+ T cells. (A) 
NK cells were cocultured with ACJUR for 36 hr and then were separated from 
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ACJUR by ficoll and cocultured at the indicated ratios with 1 x 104 resting or 
PHA-activated autologous CD4+ T cells for 2 hr. The cytotoxicity of the NK cells 
is shown as the percentage of PI+ CD4+ T cells in total CD4+ T cells. Data are 
mean±SEM, n= 6, *p< 0.05, ANOVA. (B) 2 x 105 ACJUR-treated NK cells were 
cocultured with 4 x 105 PHA activated autologous CD4+ T cells for 2 hr. The 
percentage of CD107a+ NK cells after ACJUR treatment was determined by flow 
cytometry. The data are representative of 4 independent experiments. (C) 
Combined data for the expression of CD107a on NK and ACJUR-treated NK cells 
cultured with PHA-activated autologous CD4+ T cells at the indicated ratios (n= 
4). *P < 0.05, ANOVA. 
 
Figure 6. 
ACJUR-treated NK cells mediate lysis of autologous activated CD4+ T cells 
through NKp46. NK cells were cocultured with apoptotic Jurkat T cells for 36 hr. 
(A) The surface expression of NKp30, NKp44 and NKp46, and NKG2D of NK 
cells were investigated. Results shown are representative of 5 independent 
experiments. (B) Expression levels of NKp46 (MFI) as determined by flow 
cytometry. (C) 5 x 105 ACJUR-treated NK cells were pre-incubated with saturating 
amounts of each of the indicated blocking antibodies (10-20 µg/ml) for 30 min. 1 
x 104 PHA-activated autologous CD4+ T cells were then added and cytotoxicties 
relative to isotype control were determined. Data are displayed as the mean ± 
SEM of at least of 4 independent experiments. * P < 0.05 by (B) paired t-test and 
(C) ANOVA. 
 
 37 
Figure 7. 
NKp46 recognizes activated autologous CD4+ T cells through vimentin. (A) 
The percentages of vimentin-expressing cells in resting, PHA-activated  and 
PMA/Ionomycin-activated CD4+ T cells were determined by flow cytometry 
using a goat anti-human vimentin Ab and an FITC-conjugated secondary rabbit 
anti-goat IgG antibody. (B) PHA-activated CD4+ T cells were incubated with or 
without anti-vimentin (20µg/ml) before addition of NKp46-Ig fusion protein 
(25µg/ml). Flow cytometry using FITC-conjugated secondary anti-human IgG 
antibody was used to determine NKp46-Ig fusion protein binding. Results are 
representative of 3 independent experiments. (C) 1 x 104 PHA-activated 
autologous CD4+ T cells were pre-incubated with anti-vimentin antibody, added 
to 5 x 105 ACJUR-treated NK cells that were either untreated or had been 
pre-incubated with anti-NKp46 for 30 minutes. Cytotoxicties relative to isotype 
control were then determined. Data are showed as the mean ± SEM for 4 
independent experiments. * P < 0.05; ** P < 0.005, ANOVA. 
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Figure 1. AC-treated NK cells released TGF-β1 to inhibit self production of 
IFN-γ. 
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Figure 2. The interaction of NK cells with PS induces TGF-β1 production.
g P
S
µ0
g P
S
µ
25
g P
S
µ
50
 
0
50
100
150
200
250
TG
F-
β 1
 (p
g/
m
l)
** 
* 
B 
g P
S
µ0
g P
S
µ
50 
0
5
10
15
TG
F-
β 1
 +
ve
 c
ell
s (
%
)
* 
TGF-ß1 
 
C
D
56
 
 
0 µg PS 50 µg PS 
12.4 1.5 
C 
A 
NK JU
R
+A
C
PL
B
+A
C
0
50
100
150
TG
F-
β
1 
(p
g/
m
l)
* * 
 40 
Figure 3. PS-treated NK cells inhibit proliferation and activation of CD4+ T 
cells. 
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Figure 4. PS-treated NK cells inhibit proliferation and activation of CD4+ 
cells through TGF-β1. 
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Figure 5. ACJUR-treated NK cells mediate lysis of autologous activated CD4+ 
T cells. 
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Figure 6. ACJUR-treated NK cells mediate lysis of autologous activated CD4+ 
T cells through NKp46. 
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Figure 7. NKp46 recognizes activated autologous CD4+ T cells through 
vimentin 
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Figure S1.  
Induction of apoptotic cells by UV irradiation. Live Jurkat T cells and primary 
CD4+ T cells were induced to undergo apoptosis by UV irradiation as described in 
Materials and Methods. After 50 hr of UV irradiation, more than 95% of Jurkat T 
cells and primary CD4+ T cells became annexin V and propidium iodide double 
positive. Representative of 3 independent experiments. AxV: annexin V; PI: 
propidium iodide. 
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Figure S2.  
IgG opsonized ACJUR but not live Jurkat T cell. The cells were incubated with 
or without purified human IgG (1mg/ml) for 1 hr and washed by PBS. A FITC 
conjugated secondary anti-human IgG antibody was used to elevate the binding 
(thin line, cells incubate with human IgG; thick line, cells incubate without human 
IgG). Δ represented the change in mean fluorescence level between the cells with 
secondary antibody alone versus cells with human IgG followed by secondary 
antibody. Representative of 3 independent experiments. 
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UFigure S3. 
U pregulation of NKp46 and cytotoxicity of AC-treated NK cells were 
independent to PS. (A) NK cells were incubated with ACJUR or ACPLB and 
observed that both treatments showed upregulated NKp46 expressions, and they 
were significantly higher than untreated NK cells (* P < 0.05; ANOVA was used 
to compare the different.).  (B) Moreover, PS-treated NK cells did not show 
increase cytotoxicity against autologous PHA-activated CD4+ T cells. (A-B) Data 
are displayed as the mean ± SEM for 4 independent experiments.  
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Figure S1. Induction of apoptotic cells by UV irradiation 
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Figure S2. IgG opsonized ACJUR but not live Jurkat T cell. 
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Figure S3. Upregulation of NKp46 and cytotoxicity of AC-treated NK cells 
were independent to PS.  
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